Jemperli (dostarlimab) data show 76% of patients with MSI-H/dMMR locally advanced rectal cancer achieved a complete response

Дата публикации: 24-10-2026 23:00:33

Patients had no evidence of cancer following treatment with Jemperli alone, as confirmed by endoscopy, radiology and/or pathology

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer	0	10.91	19-10-2026
2	FDA OKs Jemperli for locally advanced rectal cancer	0	10.88	19-10-2026
3	GSK presents positive data for Mo-Rez in platinum-resistant ovarian cancer	0	19.5	23-10-2026
4	Una esperanza contra la metástasis del cáncer colorrectal	0	7.2	24-10-2026
5	Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma	0	5	02-07-2026
6	Nivolumab-Ipilimumab for Gastric/Gastroesophageal Junction Adenocarcinoma	0	17.25	15-10-2026
7	FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma	0	13.78	19-10-2026
8	FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer	5	5	08-07-2026
9	Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma	0	5	09-07-2026
10	Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor	0	25.38	12-10-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.24. Источник: www.gsk.com.